THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.7] ID: TIP-MED-000191

Oral Iron Salts (Ferrous Sulphate, Ferrous Ascorbate & Ferrous Fumarate)

Active Ingredient / Scientific Identity: Oral Iron Salts • Class: Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Minerals (Essential for Haemoglobin, Myoglobin & Cytochrome Synthesis)

⚖️ Compare Profile
Generic / Entity NameOral Iron Salts (Ferrous Sulphate, Ferrous Ascorbate & Ferrous Fumarate) ([10.7])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassOral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Minerals (Essential for Haem
Available Dosage FormsOral Tablets: Delivering 47 mg to 100 mg Elemental Iron (+ Folic Acid 0.5–1.5 mg ± Zinc/B12); Oral Syrups/Drop
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chr
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Oral Iron Salts (Ferrous Sulphate, Ferrous Ascorbate & Ferrous Fumarate) (TIP-MED-000191, Reference Code [10.7]) is classified under Vitamins, Minerals & Nutrition — Haematinics & Iron Therapy (Ch 10) as a Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Minerals (Essential for Haemoglobin, Myoglobin & Cytochrome Synthesis). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.7], p. 130): • Ferrous Ascorbate (100 mg elemental Fe + Folic Acid 1.5 mg): Orofer-XT (Emcure), Livogen-XT (P&G), Ferium-XT, Autrin-XT. • Ferrous Fumarate (~33% elemental Fe): Livogen, Autrin (Pfizer), Hemsi. • Ferrous Sulphate (20% elemental Fe): Fefol (GSK—150 mg dried FeSO4 = 47 mg elemental Fe + Folic acid 0.5 mg), CGHS/Jan Aushadhi IFA tablets. • Parenteral IV Iron: Orofer-FCM / Encicarb (Ferric Carboxymaltose 500 mg/10 mL, 1000 mg/20 mL), Iron Sucrose (Orofer-S 100 mg/5 mL) — Strengths & Dosage Forms: Oral Tablets: Delivering 47 mg to 100 mg Elemental Iron (+ Folic Acid 0.5–1.5 mg ± Zinc/B12); Oral Syrups/Drops; IV Injection: Iron Sucrose 20 mg/mL (5 mL), Ferric Carboxymaltose 50 mg/mL (10 mL, 20 mL)
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.7], p. 130): • Ferrous Ascorbate (100 mg elemental Fe + Folic Acid 1.5 mg): Orofer-XT (Emcure), Livogen-XT (P&G), Ferium-XT, Autrin-XT. • Ferrous Fumarate (~33% elemental Fe): Livogen, Autrin (Pfizer), Hemsi. • Ferrous Sulphate (20% elemental Fe): Fefol (GSK—150 mg dried FeSO4 = 47 mg elemental Fe + Folic acid 0.5 mg), CGHS/Jan Aushadhi IFA tablets. • Parenteral IV Iron: Orofer-FCM / Encicarb (Ferric Carboxymaltose 500 mg/10 mL, 1000 mg/20 mL), Iron Sucrose (Orofer-S 100 mg/5 mL) — Strengths & Dosage Forms: Oral Tablets: Delivering 47 mg to 100 mg Elemental Iron (+ Folic Acid 0.5–1.5 mg ± Zinc/B12); Oral Syrups/Drops; IV Injection: Iron Sucrose 20 mg/mL (5 mL), Ferric Carboxymaltose 50 mg/mL (10 mL, 20 mL)
Dosage Forms & Available Strengths:
Oral Tablets: Delivering 47 mg to 100 mg Elemental Iron (+ Folic Acid 0.5–1.5 mg ± Zinc/B12); Oral Syrups/Drops; IV Injection: Iron Sucrose 20 mg/mL (5 mL), Ferric Carboxymaltose 50 mg/mL (10 mL, 20 mL)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Minerals (Essential for Haemoglobin, Myoglobin & Cytochrome Synthesis) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — Haematinics & Iron Therapy (Ch 10): clinical efficacy is mediated via Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Minerals (Essential for Haemoglobin, Myoglobin & Cytochrome Synthesis) for Prevention and treatment of Iron Deficiency Anaemia (IDA—microcytic hypochromic anaemia) in pregnancy/lactation, menorrhagia, nutritional deficiency, chronic GI blood loss (hookworm, peptic ulcer, haemorrhoids), and Chronic Kidney Disease (on erythropoietin therapy)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Prevention and treatment of Iron Deficiency Anaemia (IDA—microcytic hypochromic anaemia) in pregnancy/lactation, menorrhagia, nutritional deficiency, chronic GI blood loss (hookworm, peptic ulcer, haemorrhoids), and Chronic Kidney Disease (on erythropoietin therapy)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Therapeutic IDA (Modern Hepcidin-Aware Regimen): 60 mg to 100 mg Elemental Iron ONCE DAILY or ON ALTERNATE DAYS (Recent clinical haematology studies prove that taking 60–100 mg elemental iron once daily or on alternate mornings achieves higher fractional absorption and 50% fewer GI side effects than old TDS dosing, because a single iron dose triggers a 24-hour hepatic hepcidin surge that blocks subsequent doses taken the same day!). Prophylaxis: 60 mg elemental iron + 500 mcg folic acid OD. Follow physician prescription.

Administration & Meal Timing: Best absorbed on an EMPTY STOMACH (1 hour before or 2 hours after meals) with plain water or Vitamin C / Nimbu Pani (lemon water)! However, if epigastric pain or nausea occurs, take immediately after a meal (avoiding milk, tea, coffee, or calcium at that meal!). | Mid-morning (e.g., 10:30–11:00 AM, 2 hours after breakfast and 2 hours before lunch) or before dinner—safely separated from 6 AM Levothyroxine and 2 PM Calcium!

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chronic inflammation elevates hepcidin and blocks oral iron absorption—Parenteral IV Iron (Iron Sucrose or Ferric Carboxymaltose) is frequently required to maintain Transferrin Saturation (TSAT >20%) and Ferritin (>100–200 ng/mL). Hepatic: Avoid in iron-overload cirrhosis.
Elimination & Renal Adjustment:
Renal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chronic inflammation elevates hepcidin and blocks oral iron absorption—Parenteral IV Iron (Iron Sucrose or Ferric Carboxymaltose) is frequently required to maintain Transferrin Saturation (TSAT >20%) and Ferritin (>100–200 ng/mL). Hepatic: Avoid in iron-overload cirrhosis.
Hepatic Impairment Considerations:
Renal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chronic inflammation elevates hepcidin and blocks oral iron absorption—Parenteral IV Iron (Iron Sucrose or Ferric Carboxymaltose) is frequently required to maintain Transferrin Saturation (TSAT >20%) and Ferritin (>100–200 ng/mL). Hepatic: Avoid in iron-overload cirrhosis.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in Anaemia NOT caused by iron deficiency (such as Beta-Thalassaemia Trait/Major, sideroblastic anaemia, or haemolytic anaemia—giving iron in thalassaemia trait causes dangerous hepatic/cardiac iron overload!), haemochromatosis, and active peptic ulcer. Keep strictly out of reach of young children (accidental paediatric ingestion of >20–60 mg/kg elemental iron causes fatal haemorrhagic gastroenteritis and shock!).

Key Clinical Precautions: Renal: In CKD Stage 3–5 and haemodialysis patients (especially those receiving Erythropoiesis-Stimulating Agents [ESAs]), chronic inflammation elevates hepcidin and blocks oral iron absorption—Parenteral IV Iron (Iron Sucrose or Ferric Carboxymaltose) is frequently required to maintain Transferrin Saturation (TSAT >20%) and Ferritin (>100–200 ng/mL). Hepatic: Avoid in iron-overload cirrhosis.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Harmless black or dark-green tarry discolouration of stools (unabsorbed iron reacts with colonic sulphides), epigastric cramping, nausea, metallic taste, constipation (or occasional diarrhoea). (Ferrous Ascorbate [Orofer-XT] has higher stability and better GI tolerance than raw Ferrous Sulphate).
  • Oral: Corrosive gastritis/oesophageal stricture if tablet lodges in gullet; acute iron poisoning in children. Parenteral IV Iron (Iron Sucrose / Ferric Carboxymaltose): Anaphylaxis / hypersensitivity reactions, symptomatic Hypophosphataemia and osteomalacia (specifically with repeated Ferric Carboxymaltose [FCM] infusions via FGF-23 surge!), paravenous extravasation causing permanent brown skin tattooing ('iron staining').
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Drugs Impaired by Iron Chelation (Space by ≥2–4 Hours!): Levothyroxine (space ≥4 hours!), Fluoroquinolones (ciprofloxacin, levofloxacin), Tetracyclines (doxycycline), Levodopa/Carbidopa, Methyldopa, Mycophenolate, and Bisphosphonates! 2
  • Drugs/Foods that Block Iron Absorption: Calcium Carbonate/Citrate, Magnesium/Aluminium Antacids, Proton Pump Inhibitors (pantoprazole—gastric acid is needed to keep Fe2+ reduced, though Ferrous Ascorbate partially overcomes this!), and Tea/Coffee! 3
  • Enhancer: Vitamin C (Ascorbic Acid) keeps iron in the soluble ferrous (Fe2+) state and increases absorption by 30%

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: 1. Reassure about Black Stools: Warn every patient: 'Iron tablets will turn your stool black or dark green—this is completely normal and harmless!' (However, in elderly patients also taking Aspirin, Clopidogrel, or Warfarin, distinguish harmless dull green-black iron stools from shiny, foul-smelling, sticky tar-like melaena caused by stomach bleeding!). 2. Liquid Iron Tooth Staining: Dilute paediatric/adult iron syrups in water or juice and sip through a straw (or rinse mouth after) to prevent temporary dark staining of dental enamel. 3. Never combine Iron and Calcium in the same meal slot!
  • Meal & Clock Timing Instruction: Best absorbed on an EMPTY STOMACH (1 hour before or 2 hours after meals) with plain water or Vitamin C / Nimbu Pani (lemon water)! However, if epigastric pain or nausea occurs, take immediately after a meal (avoiding milk, tea, coffee, or calcium at that meal!). (Mid-morning (e.g., 10:30–11:00 AM, 2 hours after breakfast and 2 hours before lunch) or before dinner—safely separated from 6 AM Levothyroxine and 2 PM Calcium!)
  • Missed Dose Protocol: Take as soon as remembered (away from calcium/tea); never double the dose.
  • Geriatric Dispensing Pearl: In an elderly male or postmenopausal female CGHS patient presenting with newly diagnosed Iron Deficiency Anaemia, iron is a symptom, NOT a final diagnosis—occult gastrointestinal blood loss (from Aspirin/NSAIDs, peptic ulcer, angiodysplasia, or colorectal carcinoma) must always be investigated by the physician while iron stores are replenished! Use once-daily or alternate-day dosing to prevent severe geriatric constipation.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Tablets: Delivering 47 mg to 100 mg Elemental Iron (+ Folic Acid 0.5–1.5 mg ± Zinc/B12); Oral Syrups/Drops; IV Injection: Iron Sucrose 20 mg/mL (5 mL), Ferric Carboxymaltose 50 mg/mL (10 mL, 20 mL)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.7] (p. 130)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.